Petosemtamab Generates Early Clinical Activity and Tolerability in HNSCC

The bispecific antibody petosemtamab delivered responses with a manageable safety profile in patients with advanced head and neck squamous cell carcinoma.

Related Keywords

,Akamis Bio ,Eli Lilly ,Biotechn Replimune ,Kinnate Biopharma ,Ezra Cohen ,Novartis ,California San Diego Moores Cancer Center ,Pangea Therapeutics ,Primmune Therapeutics ,Head Amp Neck Cancers ,News ,Uc San Diego Health Moores Cancer Center ,Head And Neck Squamous Cell Carcinoma ,Petosemtamab ,